Michael Crump

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.6K citations · Full text

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef et al. · Journal of Clinical Oncology · 2009 · 639 citations

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown et al. · Journal of Clinical Oncology · 2011 · 630 citations · Full text

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump, John Kuruvilla, Stephen Couban et al. · Journal of Clinical Oncology · 2014 · 454 citations · Full text